Search results
...REGISTRATIONAL TRIAL EVALUATING UPLIZNA® (INEBILIZUMAB-CDON) FOR TREATMENT OF IMMUNOGLOBULIN...
Morningstar· 5 days ago:AMGN) today announced positive topline results from its randomized, double-blind, multicenter, placebo-controlled Phase 3 clinical trial (NCT04540497) evaluating the efficacy and safety of ...
Celiac Disease: Five Things to Know
Medscape· 4 days agoCeliac disease is a chronic, immune-mediated, systemic disorder caused by intolerance to gluten — a protein present in rye, barley, and wheat grains —...
Amgen's drug meets main goal in late-stage study for rare disease
Reuters via AOL· 5 days ago(Reuters) -Amgen said on Wednesday its drug helped to reduce the risk of flares in patients with an...
Annexon (ANNX) Up as Phase III Neuro Disorder Study Meets Goals
Zacks· 5 days agoAnnexon (ANNX) jumps 31% after meeting the primary and key secondary endpoints with the low dose of...
The 9 most common food allergies and how to deal with them
The Telegraph via Yahoo News· 3 days agoAround 50 per cent of deaths from anaphylaxis are in people who’d been told their allergies were...
A Chilling Discovery Suggests This King Built Funerary Huts With Blood From 41 Sacrifice Victims
Popular Mechanics via AOL· 4 days agoFrench archeologists have now analyzed the mortar of the structure and determined that it does...
Amgen reports positive data from Phase III IgG4-RD treatment trial
Clinical Trials Arena via Yahoo Finance· 4 days agoAmgen has reported positive topline outcomes from the Phase III MITIGATE clinical trial assessing...
Amgen Seeks Expanded US Approval For Autoimmune Disease Drug Acquired Via $28B Horizon Deal
Benzinga via Yahoo Finance· 5 days agoOn Wednesday, Amgen Inc (NASDAQ:AMGN) announced topline results from its Phase 3 trial evaluating...
FDA accepts filing of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of...
Benzinga· 5 hours agoBioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that that the U.S. Food and Drug Administration (FDA) has accepted Eisai's Supplemental Biologics License Application ...
Proteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem...
Nature· 5 days agoProteomic profiling reveals diagnostic signatures and pathogenic insights in multisystem inflammatory syndrome in children.